Abstract: Objective    To compare the effect of Ranibizumab by intravitreal injection for idiopathic choroidal neovascularization lesions (ICNV). Methods    By fundus fluorescein angiography (FFA), optical coherence tomography (OCT) examination and clinical manifestation diagnosis, 36 patients(36 cases) were diagnosed as idiopathic choroidal neovascular lesions, and based on the course they were divided into group A (duration <3 months ) and B (3 months ≤ duration <6 months) . All patients underwent routine intravitreal Ranibizumab injections. The BCVA (logMAR), refraction, intraocular pressure and dilated fundus investigation were determined.  Optical coherence tomography (OCT) was used to check the positional relationship between the lesion and the fovea and to measure CMT and FFA. Results    In comparison with before treatment, BCVA and CMT were significantly improved at 3 and 6 months after treatment (P<0.05). While on the 1, 3 and 6 months after treatment, BCVA and CMT showed no significant difference between the two groups  (P>0.05), but on 6 months, the injection time in group A (1.3±0.5 times) was lower than that in group B (2.1±1.2 times) (P<0.05). Conclusion    Intravitreal injection of Ranibizumab can quickly and effectively improve the patient condition. The earlier the treatment, the lower the injection time, the risk and the cost.

Key words: Idiopathic choroid neovascularization, Course, Ranibizumab